Anti-Inflammatory and Anti-Fibrotic Signaling of the Thymosin-β4 Fragment Ac-SDKP in Experimental Systems

by | Dec 5, 2025 | Peptides

Introduction

Short bioactive peptides have emerged as precise probes for dissecting fibrosis, inflammation, and tissue remodeling in controlled laboratory settings. Among these, the tetrapeptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) is generated from the N-terminus of thymosin-β4 and is constitutively cleared by the N-domain of angiotensin-converting enzyme (ACE). Preclinical investigations indicate that Ac-SDKP interfaces with profibrotic hubs—TGF-β/Smad signaling, endothelial–mesenchymal transition (EndMT), and matrix synthesis—making it a useful tool for interrogating mechanisms that govern extracellular matrix turnover and vascular homeostasis.

Despite intense focus on single-pathway antagonism in traditional study designs, fibrogenesis typically arises from convergent inputs that couple cytokine signaling to cytoskeletal programs, immune cell polarization, and redox/ER-stress responses. Ac-SDKP is of research interest because it appears to modulate several of these axes simultaneously in cell culture and animal models, enabling hypothesis-driven exploration of pathway crosstalk (e.g., ACE/Ac-SDKP/DPP-4, TGF-β/Smad vs. ERK, and microRNA networks such as miR-29 and let-7). This systems-level footprint provides a framework to study how peptide fragments derived from larger proteins can fine-tune tissue responses without invoking exogenous receptor overdrive.

ACE–Ac-SDKP Axis and Basal Antifibrotic Tone

Ac-SDKP is continuously hydrolyzed by ACE, positioning ACE as a gatekeeper of its tissue levels. In vivo reduction of endogenous Ac-SDKP has been observed to favor collagen accumulation in heart and kidney, suggesting Ac-SDKP may provide basal antifibrotic tone in experimental models. Investigators have leveraged ACE inhibition to elevate endogenous Ac-SDKP and then parsed downstream readouts—collagen deposition, myofibroblast markers, and immune infiltration—to map causal links between ACE activity and matrix remodeling in rodents.

Endothelial–Mesenchymal Transition and microRNA Crosstalk

EndMT couples endothelial plasticity to fibrosis via TGF-β receptors and downstream Smad programs. In cultured endothelial cells exposed to TGF-β family stimuli, Ac-SDKP has been reported to preserve endothelial identity by restoring antifibrotic microRNAs (miR-29s and let-7s) and by dampening DPP-4 expression, a cofactor associated with mesenchymal conversion. In diabetic-mouse kidneys, raising Ac-SDKP (via ACE blockade with or without exogenous Ac-SDKP) corresponded with reduced EndMT markers and matrix proteins, providing a tractable model for studying RNA-guided reversion of mesenchymal signaling.

TGF-β/Smad and Noncanonical ERK Modulation in Fibroblasts

Across cardiac and pulmonary fibroblast systems, Ac-SDKP has been shown to inhibit TGF-β1-induced profibrotic signaling: decreased Smad2/3 phosphorylation, maintenance of Smad7 checkpoints, and attenuation of ERK1/2 activation. Functionally, these changes align with reduced α-SMA incorporation into stress fibers, lower collagen I/fibronectin output, and restrained proliferation in vitro. These datasets enable mechanistic mapping of how a minimal peptide can recalibrate both canonical transcriptional and noncanonical mitogen pathways that converge on myofibroblast differentiation.

Macrophage Polarization and Matrix Metalloproteinase Activity

Post-injury cardiac models exhibit early inflammatory surges dominated by M1-skewed macrophages and heightened MMP-9 activity, which can destabilize infarct architecture. In rodent infarction paradigms, Ac-SDKP has been observed to lower M1 macrophage infiltration and limit MMP-9 activation without suppressing neutrophil abundance, thereby disentangling matrix-degrading pressure from necessary debridement. In radiation-associated remodeling, Ac-SDKP localized to macrophage perinuclear regions and curtailed Mac-2 (galectin-3)–linked fibroinflammatory cascades, offering a platform to study peptide-immune interfaces during sterile injury.

Cardiac Remodeling in Radiation and Ischemic Contexts

Thoracic-irradiation models show cardiomyocyte loss, extracellular matrix expansion, and contractile impairment. Investigators report that Ac-SDKP reduced apoptosis signals (e.g., TUNEL reactivity), preserved myocyte nuclear density, and limited fibrotic expansion. In acute coronary ligation models, experimental administration aligned with lower rupture incidence and mortality, correlating with the macrophage and MMP signatures above. Collectively, these systems permit interrogation of how peptide-mediated signaling intersects with biomechanical stability during adverse remodeling.

Pulmonary Fibrosis, Osteoclast-Like Programs, and RANKL Signaling

Silica-challenged rodent lungs provide a robust fibrotic model with myofibroblast foci and osteoclast-like phenotypes in macrophages. In vitro, Ac-SDKP reduced TRAP positivity and downshifted the RANKL/RANK/NFATc1/AP-1 cascade in alveolar macrophages, while in vivo it attenuated TGF-β1/AT1R/SRF expression and collagen deposition in silicotic nodules. Complementary skeletal readouts indicated preservation of bone mineral density in exposed animals, implicating shared transcriptional circuitry between lung macrophages and osteoclast differentiation that can be probed with Ac-SDKP.

Neural Inflammation, ER Stress, and Oxidative Signaling

In experimental autoimmune encephalomyelitis (EAE), a model of neuroinflammation, Ac-SDKP has been associated with reduced hippocampal CD4+ T-cell infiltration, dampened microglial/astrocytic activation, and mitigation of ER-stress markers (CHOP, caspase-12). Parallel antioxidant signatures—decreased ROS and lipid peroxidation, increased glutathione, GPx activity, and heme-oxygenase levels—were accompanied by partial preservation of myelin architecture. These findings enable controlled evaluation of peptide effects on the ER-stress/oxidative axis that often couples to inflammatory demyelination.

Cytoskeletal Programs and MRTF/SRF Pathways

Angiotensin II– or TGF-β–driven myofibroblast conversion depends on Rho-GTPase–mediated actin remodeling and nuclear translocation of MRTF-A/SRF. In human and rodent fibroblast preparations, Ac-SDKP lowered α-SMA and collagen I alongside downregulation of MRTF-A/SRF readouts, while Epac1-linked signaling appeared to counterbalance Ang II–induced cytoskeletal priming. These data sets are useful for deconvoluting how peptide cues intersect with mechanotransductive transcription networks.

Hematopoietic Quiescence and Experimental Chemoprotection

Historically, Ac-SDKP was identified as a negative regulator of hematopoietic stem-cell cycling, restraining G1→S progression in vitro. This quiescence phenotype provides an experimental handle for studying cell-cycle gating in progenitor pools and for modeling how endogenous ACE processing calibrates stem-cell dynamics under inflammatory or cytotoxic stress in non-clinical laboratory systems.

Conclusion

Across diverse cellular and animal models, Ac-SDKP consistently maps to nodal regulators of fibrosis and inflammation: it restrains TGF-β/Smad and ERK signaling, preserves endothelial identity via miR-29/let-7 circuits, modulates macrophage polarization and MMP activity, and blunts cytoskeletal transcriptional drivers of myofibroblast conversion. In neural and pulmonary paradigms, it additionally interfaces with ER-stress and RANKL-dependent programs. These convergent observations position Ac-SDKP as a compact molecular tool for probing multi-axis control of tissue remodeling in experimental systems. Further laboratory investigation is warranted to define dose-response relationships in vitro, delineate receptor-proximal events, and resolve the kinetics of ACE-dependent clearance that shape tissue exposure in preclinical models.

References

  1. Masuyer G. et al., 2015, Scientific Reports, 10.1038/srep13742
  2. Nakagawa P. et al., 2018, PLoS One, 10.1371/journal.pone.0190300
  3. Jin F. et al., 2021, Journal of Inflammation Research, 10.2147/JIR.S306883
  4. Xu H. et al., 2012, PLoS One, 10.1371/journal.pone.0040301
  5. Srivastava S.P. et al., 2020, Genes, 10.3390/genes11020211
  6. Li S. et al., 2019, Toxicology and Applied Pharmacology, 10.1016/j.taap.2019.02.015
  7. Kumar N., Yin C., 2018, Pharmacological Research, 10.1016/j.phrs.2018.07.006
  8. Peng H. et al., 2010, American Journal of Physiology – Heart and Circulatory Physiology, https://doi.org/10.1152/ajpheart.00464.2009
  9. Li S. et al., 2014, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, PubMed 25579022
  10. Xu H. et al., 2012, PLoS One, 10.1371/journal.pone.0040301
  11. Pejman S. et al., 2020, Brain Research Bulletin, 10.1016/j.brainresbull.2019.09.014
  12. Sharma U.C. et al., 2018, Circulation: Heart Failure, 10.1161/CIRCHEARTFAILURE.117.004867
  13. Cavasin M.A. et al., 2007, Hypertension, 10.1161/HYPERTENSIONAHA.106.084103
  14. Kassem K.M. et al., 2019, Canadian Journal of Physiology and Pharmacology, 10.1139/cjpp-2018-0570

Disclaimer: The information provided is intended solely for educational and scientific discussion. The compounds described are strictly intended for laboratory research and in-vitro studies only. They are not approved for human or animal consumption, medical use, or diagnostic purposes. Handling is prohibited unless performed by licensed researchers and qualified professionals in controlled laboratory environments.

Related Products